中国药物警戒2024,Vol.21Issue(5) :563-566.DOI:10.19803/j.1672-8629.20230381

吡拉西坦制剂安全性风险分析及思考

Risks of piracetam preparations to safety

刘翠丽 吴晨 王涛
中国药物警戒2024,Vol.21Issue(5) :563-566.DOI:10.19803/j.1672-8629.20230381

吡拉西坦制剂安全性风险分析及思考

Risks of piracetam preparations to safety

刘翠丽 1吴晨 1王涛1
扫码查看

作者信息

  • 1. 国家药品监督管理局药品评价中心,国家药品监督管理局药物警戒研究与评价重点实验室 北京 100076
  • 折叠

摘要

目的 分析吡拉西坦制剂安全性风险,为临床合理用药提供参考.方法 对 2004 年1月1日至 2023年3月31日国家药品不良反应监测数据库中吡拉西坦制剂的不良反应发生特点及临床表现进行汇总;对 2000 年1月至 2023年3月31日国内文献数据库相关不良反应报道进行整理;对国内风险控制措施进行分析.结果 2004 年1月1日至 2023年3月31日,共有吡拉西坦制剂不良反应病例报告40 675例,其中严重病例1 922例(4.7%).口服制剂不良反应病例报告5 360 例,其中严重不良反应报告55例,新的不良反应报告429 例.注射制剂不良反应病例报告35 315例,其中严重病例1 865例(5.3%).结论 吡拉西坦制剂可致过敏性休克等严重不良反应,临床应用需注意并做好相关防治措施,药品上市许可持有人应加强不良反应监测与评价的主体责任,及时完善吡拉西坦制剂说明书安全性信息.

Abstract

Objective To analyze the risk of piracetam preparations in order to provide reference for clinical rational drug use.Methods Individual cases of adverse drug reactions reported in China adverse drug reaction(ADR)database between January 1,2004 and March 31,2023,domestic literature published from January 1,2000 to March 31,2023 and risk control measures taken in China were analyzed.Results Between January 1,2004 and March 31,2023,there were a total of 40 675 ADR reports of piracetam preparations in the database,involving 1 922 serious cases(4.7%).There were 5 360 ADR reports of oral preparations,including 55 serious adverse reactions and 429 unexpected adverse reactions.There were 35 315 cases of ADR reports of injection preparations,including 1 865 serious cases(5.3%).Conclusion Piracetam preparations can cause serious adverse reactions such as anaphylactic shock.Clinicians should be alert to these serious adverse reactions and take preventions when prescribing piracetam preparations.Marketing authorization holders should assume more responsibility for monitoring and evaluation of adverse drug reactions and update the information on safety in drug labels in time.

关键词

吡拉西坦/药品不良反应/风险/监管措施/安全性/说明书

Key words

piracetam/adverse drug reaction/risk/regulatory measures/safety/instruction

引用本文复制引用

基金项目

国家自然科学基金(72274065)

药品监管科学体系建设重点项目(RS2024G001)

出版年

2024
中国药物警戒
国家药品监督管理局药品评价中心(国家药品不良反应监测中心)

中国药物警戒

CSTPCD
影响因子:1.105
ISSN:1672-8629
参考文献量11
段落导航相关论文